share_log

8-K: Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages

8-K: Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages

8-K:Biote公佈2024年第三季度財務業績持續盈利增長縱向整合推動毛利率提高推出專有臨床決策支持軟件以增強競爭優勢
美股SEC公告 ·  11/12 16:26
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息